Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05442177

Enrollment

Registered

2022-07-01

Start date

2015-07-01

Completion date

2016-06-30

Last updated

2022-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelosuppression

Keywords

Traditional Chinese Medicine; radial pulse assessment; sphygmography; pulse diagnosis; myelosuppression; cancer

Brief summary

We conducted an observational study to investigate the effectiveness and safety of Integrated Chinese Medicine With Western Medicine for bone marrow suppression induced by chemotherapy in patients with cancer. The TCM constitution and pulse diagnosis was also observed in the study.

Detailed description

Patients with cancer under chemotherapy and integrated Western and Chinese medicine were enrolled in this observational study. The assessment of radial pressure pulse (RPP) was performed before and after chemotherapy. The correlation between the spectral energy (SE0-10 Hz, SE10-50 Hz, and SE13-50 Hz) of the RPP at six diagnosis positions and the blood cell counts before and after chemotherapy were analyzed.

Interventions

PROCEDUREChemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* Patients with cancer diagnosed through pathological histology * Patients with cancer under chemotherapy and Integrated Chinese Medicine With Western Medicine * Patients with an Eastern Cooperative Oncology Group Performance score of 0-2 * Patients having normal liver and kidney functions and electrocardiography and eligible for chemotherapy with normal bone marrow hematopoietic function * Patients who were voluntarily involved in this study

Exclusion criteria

* Cases that did not meet the inclusion criteria * Patients who could not cooperate with pulse diagnosis * Patients with underlying diseases such as chronic obstructive pulmonary disease, cardiac failure, chronic renal failure, cirrhosis, etc. * Patients with severe infection * Patients with severe cachexia

Design outcomes

Primary

Measure	Time frame	Description
Chemotherapy-induced Hematologic Toxicity	one month	the blood cell count before and after chemotherapy was collected for measurement of severity of myelosuppression

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026